Charles Morris

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Malcolm Ranson, Lisa A. Hammond, D. K. Ferry et al. · Journal of Clinical Oncology · 2002 · 763 citations

Medicine, Oncology, Pharmacology +14

Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American Trial

C. Kent Osborne, John Pippen, Stephen E. Jones et al. · Journal of Clinical Oncology · 2002 · 643 citations

Medicine, Oncology, Pharmacology +14

Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational, Double-Blind, Randomized Trial

Anthony Howell, J.F.R. Robertson, P. Abram et al. · Journal of Clinical Oncology · 2004 · 425 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women

J.F.R. Robertson, C. Kent Osborne, Anthony Howell et al. · Cancer · 2003 · 313 citations · Full text

Medicine, Oncology, Pharmacology +16

Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.

J.F.R. Robertson, Robert I. Nicholson, NJ Bundred et al. · PubMed · 2001 · 216 citations · Full text

Medicine, Oncology, Pharmacology +16